2,3 DINOR 11B PROSTAGLANDIN F2A,URINE

Sample type: Urine

Other names: 2, 3-dinor 11B-Prostaglandin F2a, U

Optimal result: 0 – 5205 pg/mg Cr

2,3-dinor-11β-Prostaglandin F2α (urine) is a stable downstream metabolite of prostaglandin D2 (PGD2)—a mast-cell–derived lipid mediator—measured in spot or 24-hour urine (typically by LC-MS/MS and normalized to creatinine) to provide a noninvasive index of in-vivo PGD2 production and mast-cell activation. Elevated values, interpreted against the lab’s own reference range, can support conditions with mediator release such as mast cell activation syndrome or systemic mastocytosis, allergic reactions and anaphylaxis, aspirin/NSAID-exacerbated respiratory disease, atopic asthma, allergic rhinitis, and chronic spontaneous urticaria; however, it is a supportive—not standalone—marker and should be correlated with symptoms and companion tests (e.g., serum tryptase—including event-related rise of baseline +20%+2 ng/mL—urinary N-methylhistamine, and urinary leukotriene E4). Results are time-sensitive to flares (collect as close to symptoms as possible), and medications can shift levels: NSAIDs/COX-2 inhibitors often suppress prostaglandin synthesis; corticosteroids and mast-cell stabilizers may lower levels over time; biologics and leukotriene modifiers can alter patterns. Normal results do not exclude mast-cell activation due to intermittent release; very low levels may reflect COX inhibition or effective therapy. For trending, use the same lab/method, verify units (e.g., pg/mg creatinine), and document a baseline and flare sample when feasible.

2,3-dinor-11β-PGF2α is a urinary metabolite of prostaglandin D2 (PGD2)—a lipid mediator produced from arachidonic acid via the cyclooxygenase (COX) pathway. Mast cells are a major source of PGD2. After PGD2 is released in tissues, it is rapidly converted into more stable downstream metabolites, including 11β-PGF2α and 2,3-dinor-11β-PGF2α, which are excreted in urine. Measuring these metabolites provides a noninvasive index of in-vivo PGD2 production and, by extension, mast-cell activation.

Also known as:

  • 2,3-dinor-11β-PGF2α (urine)

  • Dinor-11β-PGF2α, U

  • PGD2 metabolite (urine)

  • u-PGD2-M (terminology varies by lab)

Why it matters

PGD2 is a potent bioactive mediator that can cause bronchoconstriction, vasodilation, increased vascular permeability, flushing, and nasal congestion. Elevated urinary PGD2 metabolites are therefore used as supportive evidence in conditions featuring mast-cell activation, such as:

  • Mast Cell Activation Syndrome (MCAS) and systemic mastocytosis

  • Aspirin-exacerbated respiratory disease (AERD) / NSAID-exacerbated respiratory disease

  • Allergic reactions and anaphylaxis (often transient spikes)

  • Chronic spontaneous urticaria, atopic asthma, allergic rhinitis

  • Some cutaneous mastocytosis flares and food/venom allergies during reactions

Important: This marker is supportive, not diagnostic on its own. It is typically interpreted alongside clinical symptoms and companion markers (e.g., serum tryptase, urinary N-methylhistamine, urinary leukotriene E4 [uLTE4]).

How the test is done

  • Specimen: Urine (often a spot sample normalized to creatinine; some centers may request a 24-hour collection).

  • Method: Usually LC-MS/MS for specificity and sensitivity.

  • Reporting units: Commonly pg/mg creatinine or ng/mmol creatinine (varies by laboratory).

  • Stability/handling: Keep cool; follow lab instructions carefully—improper handling can affect results.

Reference ranges

There is no universal cut-off. Reference intervals and decision thresholds vary by lab, assay, and whether the sample is a spot vs. 24-hour collection. Always compare your value with the lab’s own reference range on the report.

How to interpret results

Elevated u-2,3-dinor-11β-PGF2α (above lab reference)

Suggests increased PGD2 pathway activity, commonly due to mast-cell activation. Consider the clinical context:

  • Symptoms consistent with mast-cell mediator release (flushing, wheeze/bronchospasm, nasal congestion/rhinorrhea, abdominal cramping/diarrhea, hypotension during reactions).

  • Co-elevations in urinary N-methylhistamine, uLTE4, or a rise in serum tryptase during episodes (Δ tryptase ≥20% + 2 ng/mL over baseline supports mast-cell involvement).

  • Recent allergen exposure, anaphylaxis, or NSAID challenge in AERD can produce transient spikes.

Non-disease contributors / confounders (can raise or alter levels):

  • Medications:

    • COX inhibitors (NSAIDs, high-dose aspirin) generally suppress prostaglandin synthesis; however, in AERD, reactions to aspirin/NSAIDs are complex and can be accompanied by transient mediator surges during provocation.

    • Corticosteroids and mast-cell stabilizers (e.g., cromolyn) may lower levels over time.

  • Active infections, acute inflammation, or vigorous allergic exposure shortly before sampling.

  • Collection timing relative to symptom flares (levels can be episodic).

What to do next (clinically, with your clinician):

  • Correlate with symptom diary and consider paired sampling: one sample during/just after a flare and one baseline when asymptomatic.

  • Review companion markers (tryptase, uLTE4, N-methylhistamine).

  • Evaluate medication effects (NSAIDs, steroids, biologics like omalizumab, dupilumab; leukotriene modifiers).

  • If mast-cell disease is suspected, consider referral to allergy/immunology or hematology (for systemic mastocytosis evaluation when indicated).

Normal result

A normal value does not exclude mast-cell activation—mediator release can be intermittent and time-sensitive to flares. If suspicion remains high, clinicians often:

  • Repeat testing during symptoms,

  • Check other mediators, and

  • Assess tryptase dynamics (baseline vs. event-related rise).

Low result

Usually of limited standalone significance. Very low levels may reflect COX inhibition (e.g., steady NSAID use) or effective anti-inflammatory / anti-mast-cell therapy.

Clinical context & companion testing

Because no single mediator fits all patients or all timepoints, clinicians often combine:

  • Serum tryptase (baseline and during events),

  • Urinary leukotriene E4 (uLTE4) for cysteinyl-leukotriene pathway activity,

  • Urinary N-methylhistamine (histamine turnover),

  • Prostaglandin metabolites like 2,3-dinor-11β-PGF2α and 11β-PGF2α (PGD2 pathway).

This multi-analyte approach improves sensitivity for detecting mast-cell involvement.

Factors that can influence results

  • Timing: Collect as close to symptom onset as practical (often within 4–6 hours) for flare assessment.

  • Diet & supplements: Typically minimal effect, but always follow lab prep instructions.

  • Meds: NSAIDs/aspirin, COX-2 inhibitors, corticosteroids, mast-cell stabilizers, and certain biologics can shift levels (direction depends on drug and clinical context). Share a full med list with your clinician.

  • Renal function & hydration: Creatinine-normalized reporting helps, but extreme hydration or renal impairment can still affect interpretation.

How this marker is used in practice

  • Support diagnosis of mast-cell–mediated conditions in the right clinical setting.

  • Document objective mediator release in patients with unexplained flushing, anaphylactoid episodes, or bronchospasm.

  • Monitor response to therapy (e.g., after starting leukotriene modifiers, cromolyn, antihistamines, or biologics) when measured consistently with the same lab/method.

Practical testing tips

  • Ask whether your lab prefers a first-morning spot urine (with creatinine) or a 24-hour collection.

  • If evaluating flares, plan to collect during symptoms and consider a baseline sample on a stable day.

  • Verify units and reference range on your specific report; keep copies for comparison over time.

  • If you’re on medications that may affect prostaglandins, do not stop them without medical guidance—interpretation can account for them.

FAQs

Is this the same as 8-iso-PGF2α (F2-isoprostanes)?
No. F2-isoprostanes are markers of oxidative stress formed non-enzymatically. 2,3-dinor-11β-PGF2α reflects enzymatic PGD2 pathway activity, often tied to mast-cell activation.

Do I need both 11β-PGF2α and 2,3-dinor-11β-PGF2α?
Many labs measure one or both. Patterns can be informative, but either can serve as a surrogate for PGD2 production. Use the same lab and method for trend monitoring.

What’s a “good” level?
“Good/abnormal” depends on the lab-specific reference interval and your clinical picture. Elevated values are only actionable when correlated with symptoms and other markers.

2,3 DINOR 11B PROSTAGLANDIN F2A,URINE
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond 2,3 DINOR 11B PROSTAGLANDIN F2A,URINE — 10,000+ markers explained
One 2,3 DINOR 11B PROSTAGLANDIN F2A,URINE result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

Article Review Log
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro